baber/WOPTO huggingface dataset:
Patent NZ-565932-A (NZ)
Title: Displaying diagnostic information associated with fault codes related to system control
Inventor: JAENKE BRUCE A
IPC: G05B19/10
Filed: 2006-08-31
Abstract: Disclosed is a method of displaying diagnostic information on a display associated with a wheelchair. The method includes: storing a collection of diagnostic information associated with fault codes; receiving a selected fault code and a request for diagnostic information; and displaying the diagnostic information associated with the selected fault code on the display. The fault codes or diagnostic information are stored on a system controller mounted to a wheelchair.
Patent NZ-574865-A (NZ)
Title: Improved medical diagnostic device
Inventor: BARTLETT STEWART
IPC: A61B5/332
Filed: 2007-07-16
Abstract: A handheld medical diagnostic device includes a dedicated display and processing unit integral to the device; at least one probe unit which produces as an output medical diagnostic data and an interface which removably connects the probe unit to the display and processing unit; The display and processing unit operates to receive the diagnostic data from the probe unit. The probe unit is of a type selected from a plurality of probe unit types with each of probe unit types providing a different type of diagnostic data to allow the device to fulfil a different medical diagnostic function and each of probe unit types requires specified communication and control protocols to be implemented in order to communicate with the display and processing unit. The interface is configurable in use such that when a chosen probe unit is connected to the display and processing unit via the interface. The required communication and control protocols for the chosen probe unit are implemented without user action to configure the interface. Upon connection of a probe unit to the display and processing unit identification and specification data is communicated from the probe unit to the display and processing unit indicating the nature and function of the diagnostic data output by the probe unit. The display and processing unit then runs programs to process, and analyse and display the diagnostic data in a manner suitable for the nature of the diagnostic data.
Patent NZ-580940-A (NZ)
Title: Process for preparing an a2a-adenosine receptor agonist and its polymorphs
Inventor: ZABLOCKI JEFF
IPC: C07H19/167
Filed: 2007-05-17
Abstract: Disclosed is a method of synthesizing (1-{ 9-[(4S,2R,3R,sR)-3,4-dihydroxy-s-(hydroxymethyl)oxolan-2-yI]-6-aminopurin-2-yl} pyrazol-4-yl)-N-methylcarboxamide, a compound of formula (4) and a compound of formula (A) (as depicted).
Patent NZ-581439-A (NZ)
Title: Fluid dispenser with a piston sealingly movable in a dosing chamber but only in sealing contact with a narrower first section during a part of the stroke.
Inventor: COLLINS JAMES TERENCE
IPC: B05B11/00
Filed: 2008-05-30
Abstract: A fluid dispenser (110) is disclosed comprising a dosing chamber (120), a fluid outlet and a piston member (114) which is arranged to sealingly stroke in the dosing chamber (120). Piston movement in a first direction fills the dosing chamber (120) with fluid from the supply and in a second direction dispenses fluid from the dosing chamber (120) towards the outlet. The dosing chamber (120) has a first section which is narrower than a second section and located in the second direction. The piston member (114) is in constant sealing contact with the second section but only in sealing contact with the first section during a portion of the piston strokes in the first and second directions.
Patent NZ-582873-A (NZ)
Title: 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
Inventor: BAUDOIN BERNARD
IPC: C07D413/12
Filed: 2008-07-25
Abstract: Disclosed are 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives as represented by the general formula (I), in which: R1 represents hydrogen, alkyl, cycloalkyl, (CH2)n-alkenyl, (CH2)n-alkynyl or alkyl-Z-alkyl, or else R1 represents a COOR, S(O)mR, aryl or aralkyl, wherein said alkyl, cycloalkyl, alkenyl, alkynyl, aryl or aralkyl groups are each optionally substituted; R2 represents one or more groups chosen from hydrogen, halogen, alkyl, cycloalkyl, alkenyl, alkynyl or alkyl-Z-alkyl group, or else R2 represents a haloalkyl, alkoxy, haloalkoxy, hydroxy, nitro, cyano, amino, NR7R8, COOR, CONR7R8, OCOalkyl, S(O)m-NR7R8, or an optionally substituted aryl group; R3 represents a trifluoromethyl group; R4 and R5 represent hydrogen, or else R4 and R5 form with the carbon atom that bears them, a saturated ring and which may also optionally contain one heteroatom chosen from O, N or S; R6 represents hydrogen, halogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, nitro, amino, NR7R8, COOR, NR7(SO2)R8, CONR7R8, or an optionally substituted aryl or heterocycle group; X represents a (C1-C2)alkylene group, optionally substituted with one or more alkyl groups; and wherein the remaining substituents are as defined herein. Important representative compounds include N-[(1S,2R)-1-benzyl-2-hydroxy-3-{ [3-(trifluoromethyl)benzyl]amino} propyl]-1-oxo-2-(1-propylbutyl)isoindoline-4-carboxamide and its hydrochloride (1:1); N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({ 1-[3-(trifluoromethyl)phenyl]cyclopropyl} amino)propyl]-7-[methyl(methylsulfonyl)amino]-1-oxo-2-(1-propylbutyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide and its hydrochloride (1:1); N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({ 1-[3-(trifluoromethyl)phenyl]cyclopropyl} amino)propyl]-7-(3-cyanophenyl)-1-oxo-2-(1-propylbutyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide and its hydrochloride (1:1) and N-[(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-({ 1-[3-(trifluoromethyl)phenyl]cyclopropyl} amino)propyl]-7-(2-cyanophenyl)-1-oxo-2-(1-propylbutyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide and its hydrochloride (1:1). Further disclosed is a medicament which comprises a compound of formula (I) as defined above, or an addition salt of the compound with a pharmaceutically acceptable acid, or a hydrate or solvate of the compound of formula (I), for treating and for preventing Alzheimer's disease, Parkinson's disease, Huntington's disease, Creutzfeldt-Jakob disease, Down's syndrome, dementia with Lewy bodies, senile dementia, frontotemporal dementia, cerebral and systemic amyloidosis, mild cognitive impairments, cerebral amyloid angiopathy, primary and secondary memory disorders, amyotrophic lateral sclerosis, multiple sclerosis, peripheral neuropathies, diabetic neuropathies, migraine, mood disorders, depression, anxiety, vascular disorders, and cell proliferation disorders.
Patent NZ-583164-A (NZ)
Title: Using relative displacement and relative velocity to obtain absolute displacement with phase compensation
Inventor: SETO KAZUTO
IPC: G01B21/00
Filed: 2008-08-05
Abstract: An absolute displacement sensor (1) is disclosed. The sensor includes a sensor housing (2) as a detection object; a mass body (3) which has a mass m and is movably supported by the sensor housing (2) with a spring coefficient k and an attenuation coefficient c; detection means (4) which electrically detects a relative velocity of the sensor housing (2) for the mass body (3); feedback control means (5). The feedback control means (5) feeds back a relative displacement using positive feedback and a relative acceleration obtained by primary differentiation of the relative velocity using negative feedback so as to control an absolute displacement of the mass body (3) caused by the absolute displacement of the sensor housing (2). Phase delay compensation means (6) performs phase delay compensation on the relative displacement.
Patent NZ-587233-A (NZ)
Title: Methods and compositions comprising trichoderma atroviride for the biological control of soil borne plant pathogens and promoting plant growth
Inventor: STEWART ALISON
IPC: A01N63/38
Filed: 2009-02-13
Abstract: Discloses a composition and methods comprising in a reproductively viable form and amount: Trichoderma atroviride NMI No. V08/002387. Further discloses a composition which further comprises at least one additional strain of Trichoderma atroviride selected from Trichoderma atroviride NMI No. V08/002389; Trichoderma atroviride NMI No. V08/002388; and Trichoderma atroviride NMI No. V08/002390. The composition(s) finds application as a biological control agent to control selected soil borne pathogens and increase plant growth.
Patent NZ-588270-A (NZ)
Title: Recombinant antigens
Inventor: OSUNA CARRILLO DE ALBORNOZ ANTONIO
IPC: A61K38/17
Filed: 2009-02-19
Abstract: 588270 Disclosed is a vaccine comprising a peptide with SEQ ID NO: 1 or a nucleic acid molecule comprising one or more nucleotide sequences which encode the peptide identified by SEQ ID NO: 1. Further disclosed are methods for the prevention or treatment of parasitization by nematodes with a vaccine comprising a peptide identified by SEQ ID NO: 1 or having at least 80% similarity therewith. >1VVDEFCTNHNIDLILRAHQITAEMVYGGYRIFAGGRLVTIFSAPNYQNMMNDGCVMRIKRDLTANFIIFRPVVRRH
Patent NZ-588302-A (NZ)
Title: Wind turbine configuration management system with a central computer system and at least one wind turbine control system
Inventor: JENSEN MICHAEL
IPC: F03D9/00
Filed: 2009-06-08
Abstract: Disclosed is a wind turbine configuration management system which includes a central computer system having a processing unit, and at least one wind turbine control system controlling a wind turbine. The wind turbine control system is coupled to the central computer system over a communication network. The processing unit is con figured to receive configuration data from the wind turbine control system. The central computer system comprises a memory comprising configuration reference data for the wind turbine. The processing unit is configured to periodically request current configuration data from the wind turbine control system over the network. The current configuration data describes the type of the wind turbine. The processing unit compares the current configuration data to the configuration reference data.
Patent NZ-590464-A (NZ)
Title: Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
Inventor: WANG KENNETH
IPC: A61K31/4706
Filed: 2009-08-04
Abstract: Disclosed is the use of neratinib and capecitabine in the manufacture of a medicament for treating a neoplasm and particularly for the treatment of breast cancer; wherein the medicament is formulated for administration of capecitabine in an amount of about 1250mg to about 3000mg daily; or wherein the medicament is formulated for administration of neratinib in an amount of at least about 40 mg.
Patent NZ-592826-A (NZ)
Title: Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
Inventor: BIFTU TESFAYE
IPC: A61K31/4162
Filed: 2009-11-11
Abstract: Disclosed are aminotetrahydropyran compounds of formula (I), wherein the substituents are as described within the specification. An example of a compound of formula (I) includes (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine. Further disclosed is a pharmaceutical composition which comprises a compound of formula (I) and a pharmaceutically acceptable carrier, and the use of a compound of formula (I) in the manufacture of a medicament for use in treating a condition selected from the group consisting of insulin resistance, hyperglycemia, and Type 2 diabetes.
Patent NZ-595584-A (NZ)
Title: Lighting techniques for wirelessly controlling lighting elements
Inventor: WONG BRIAN
IPC: H05B37/02
Filed: 2010-03-23
Abstract: 595584 An infrared control system for controlling reactive lighting modules is disclosed. The system comprises a projector system including a two-dimensional array of separate lighting elements configured to project a two-dimensional control image including an array of sub-images with each corresponding to a respective lighting element in the two-dimensional array, through a lens and a plurality of separate reactive modules. Each reactive module includes an optical receiver and one or more lighting elements. Each module is configured to control the one or more lighting elements based on a received portion of the two-dimensional control image. The received portion of the two-dimensional control image includes a sub-image of the array of sub-images. A control system for optical control of lighting elements is also disclosed. The system comprises a two-dimensional array of separate lighting elements operative to produce a two-dimensional control image; a plurality of receiving modules included in a target space including one or more sub-spaces; a projector system configured to project the optical two-dimensional control image by use of a lens onto the target space and a plurality of lighting elements. The two-dimensional control image includes at least one sub-image which is projected onto at least one sub-space and, each lighting element is in communication with a respective and separate receiving module in the target space and with one or more optical characteristics controlled by the control signal. Also disclosed is a method of wireless transmission of a two-dimensional optical control signal to control one or more lighting elements and a method of wireless control of area lighting.
Patent NZ-596302-A (NZ)
Title: Aryl pyridine as aldosterone synthase inhibitors
Inventor: PAPILLON JULIEN
IPC: C07D213/76
Filed: 2010-05-12
Abstract: 596302 Disclosed herein are compounds of the formula I, wherein the variables are defined in the specification, and their use in the treatment of a disorder or a disease in a subject mediated by aldosterone synthase, such as hypokalemia, hypertension, Conn’s disease, renal failure, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction, cardiovascular diseases, renal dysfunction, liver diseases, cerebrovascular diseases, vascular diseases, retinopathy. neuropathy, insulinopathy, edema, endothelial dysfunction, baroreceptor dysfunction, migraine headaches, heart failure such as congestive heart failure, arrhythmia, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, impaired diastolic filling, systolic dysfunction. ischemia, hypertrophic cardiomyopathy, sudden cardiac death, myocardial and vascular fibrosis, impaired arterial compliance, myocardial necrotic lesions, vascular damage, myocardial infarction, left ventricular hypertrophy, decreased ejection fraction, cardiac lesions, vascular wall hypertrophy, endothelial thickening and fibrinoid necrosis of coronary arteries. Exemplary embodiments of the compound include the following: N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yl)ethanesulfonamide; N-(5-(3-chloro-4-cyanophenyl)pyridin-3-yI)-2,2,2-trifluoroethanesulfonamide; cyclopropanesulfonic acid[5-(3-chloro-4-cyano-phenyl)-pyridin-3-yI]-amide; (R)-N-((5-(4-cyano-3-fluorophenyl)pyridine-3-yl)(cyclopropyl)methyl) ethanesulfonamide; and N-(cyclopropyl(5-benzo[b]thiophen-2-yl-pyridin-3-yl)methyl)ethanesulfonamide;
Patent NZ-597928-A (NZ)
Title: Signal processing system and methods for reliably detecting audible alarms
Inventor: HOY LESLIE D
IPC: G08B29/18
Filed: 2010-07-29
Abstract: A signal processing system for detecting audible alert signals and a method for detecting audible alert signals implemented in signal processing circuitry are disclosed. The signal processing system comprises a circuit configured to receive an audio signal and to generate a digital representation of the received audio signal and a memory buffer configured to store a plurality of templates. Each template corresponds to an acceptable audible alert signal timing pattern, and the plurality of templates encompass an acceptable range of variation in a timing pattern of a standard audible alert signal. The signal processing system further comprises a circuit configured to compare the digital representation of the received audio signal to the respective template; generate a matching score representing a degree of match between the digital representation of the received audio signal and the respective template, and determine, based at least partly on the matching scores corresponding to the plurality of templates, whether an audible alert signal is present.
Patent NZ-601880-A (NZ)
Title: Compositions and methods of enhancing immune responses to eimeria
Inventor: BERGHMAN LUC
IPC: A61K39/00
Filed: 2008-11-03
Abstract: 601880 Disclosed is a vaccine comprising a first polynucleotide sequence encoding a TRAP polypeptide or an immunogenic fragment thereof, wherein the TRAP polypeptide is SEQ ID NO:3, or an immunogenic fragment of SEQ ID NO:3. Further disclosed is a vaccine comprising a variant of Salmonella enteritidis 13A comprising a first polynucleotide sequence encoding a TRAP polypeptide, wherein the TRAP polypeptide is SEQ ID NO:3 or an immunogenic fragment of SEQ ID NO:3.. Wherein SEQ ID NO:3 is: GGGFPTAAVAGGVGGVLLIAAVGGGVAAFTSGGGGAGAQE
Patent NZ-609947-A (NZ)
Title: Service redirection from a policy and charging control architecture
Inventor: CASTRO CASTRO FABIAN
IPC: H04L12/14
Filed: 2010-11-16
Abstract: A method of authorising a redirection service in a Policy and Charging Control (PCC) architecture is disclosed. The method comprises a Policy and Charging Enforcement Function (PCEF) device requests control rules upon an IP Connectivity Access Network (IP-CAN) session establishment or modification. A Policy and Charging control Rules Function (PCRF) server determines services requiring redirection and answers with control rules and redirection information per service basis. The PCEF device installs the control rules and the redirection information for the service for which the redirection is required. The PCEF device determines the service by the service destination identifier is the service for which the redirection is required and returns a redirection message with a redirection identifier upon a first request for a service. The first request for the service reaches the PCEF and the PCEF verifies the service is authorized and submits a service allowance towards the service server in charge of the service upon completion of the service redirection. A PCRF server adapted to determine redirection per service in an IP-CAN session and a PCEF device adapted to receive redirection information per service basis, and to determine redirection per service request and to trigger the redirection are also disclosed.
Patent NZ-614540-A (NZ)
Title: Cathepsin c inhibitors
Inventor: NEIPP CHRISTOPHER E
IPC: C07D309/14
Filed: 2012-02-09
Abstract: Disclosed herein are compounds of Formula (I) which are 4-amino-2-butenamides, where the subtituents are as defined herein. An example of these compounds being 4-amino-N-[(1S,2E)-4-(2,3-dihydro-1H-indol-1-yl)-1-ethyl-4-oxo-2-buten-1-yl]tetrahydro-2H-pyran-4-carboxamide. Also disclosed are pharmaceutical compositions containing these compounds which are useful for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease.
Patent NZ-615283-A (NZ)
Title: Asymmetric ureas and medical uses thereof
Inventor: GARCIA RUBIO SILVINA
IPC: C07D233/36
Filed: 2012-02-23
Abstract: Disclosed are 4-ureido-N-methyl-piperidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R is aryl optionally substituted with one or more independent R103 substituents; R1 is selected from the group consisting of hydroxyalkyl, alkyl, optionally substituted with one or more independent R103 substituents; R4 is selected from the group consisting of alkyl, aryl, arylalkyl, optionally substituted with one or more independent R103 substituents; or R4 is OR103; R6, R7, R8, R9 are selected from the group consisting of hydrogen and alkyl; R103 is selected from the group consisting of hydrogen, cyano, nitro, -OR104, hydroxy, amino, alkyl, alkenyl, cycloalkyl, halogen, haloalkyl, alkoxy, alkoxyalkyl, aryl, arylalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, -C(O)R104, -C(O)OR104, -C(O)NR104R105, -NR104R105, -NR104S(O)2R105, -NR104C(O)R105, -S(O)2R104, -SR104 and -S(O)2NR104R105, and R104 and R105 are each independently selected from the group consisting of hydrogen, cyano, nitro, hydroxy, hydroxyalkyl, amino, alkyl, alkenyl, cycloalkyl, halogen, alkoxy, alkoxyalkyl, aryl, arylalkyl, heterocycloalkyl, heteroaryl and heteroarylalkyl. Also disclosed are representative compounds such as 1-methyl-3-((R)-1-(naphthalen-1-yl)ethyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea, 3-(1-(4-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea, 3-(1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea, 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea, 3-(1-(2-methoxynaphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, 3-(2-cyclopropyl-1-(2,3-dichlorophenyl)ethyl)-1-(3-methoxybenzyl)-1-(1,3,3-trimethylpiperidin-4-yl)urea, 3-(2-hydroxy-1-(naphthalen-1-yl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, 1-ethyl-1-(1-methylpiperidin-4-yl)-3-(1-(naphthalen-1-yl)-3-(3-(pyridin-3-yloxy)phenyl)propyl)urea, 1-methyl-1-(1-methylpiperidin-4-yl)-3-(3-morpholino-1-(naphthalen-1-yl)propyl)urea and 3-(1-(3-chloro-2-(pyridin-4-yl)phenyl)ethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea. Also disclosed is a pharmaceutical composition comprising a therapeutically effective amount of a compound as defined above, and one or more pharmaceutically acceptable excipients, for preventing and/or treating a subject having a disease which is pathophysiologically mediated by the ghrelin receptor, including conditions such as obesity, overweight, eating disorder, diabetes, metabolic syndrome, cachexia resulting from cancer, congestive heart failure, wasting due to ageing or AIDS, chronic liver failure, chronic obstructive pulmonary disease, gastrointestinal disease, gastric disorder or substance abuse.
Patent NZ-626232-A (NZ)
Title: A splint
Inventor: KUMAR PRANESH
IPC: A61F5/37
Filed: 2013-06-12
Abstract: A splint for use in reducing a bone fracture that has produced at least a first bone fragment (7) and a second bone fragment (8) is disclosed. The the splint includes a first restraint portion (102) and a second restraint portion (104). The restraint portions can be adjusted with respect to each other to align the first bone fragment and the second bone fragment in a desired orientation that substantially corresponds to the unfractured orientation of the bone. The restraint portions are connected by a connection assembly (112) that can hold the first and second restraint portions substantially immovably with respect to each other, holding the first and second bone fragments in the desired orientation. Embodiments for wrist, ankle and meta-carpal splints are disclosed.
Patent NZ-627888-A (NZ)
Title: Materials and methods for respiratory disease control in canines
Inventor: CRAWFORD PATTI C
IPC: A61K39/00
Filed: 2006-10-19
Abstract: Disclosed is a canine influenza vaccine, wherein the vaccine comprises a therapeutically effective amount of an influenza virus that is capable of infecting a canid animal, wherein said influenza virus comprises: i) a polynucleotide which encodes a hemagglutinin (HA) polypeptide comprising the amino acid sequence shown in SEQ ID NO:78, or a functional and/or immunogenic fragment thereof, or said polynucleotide encodes a polypeptide having 98% or greater sequence identity with the amino acid sequence shown in SEQ ID NO:78; or ii) a HA polypeptide comprising the amino acid sequence shown in SEQ ID NO:78, or a functional and/or immunogenic fragment thereof, or said polynucleotide encodes a polypeptide having 98% or greater sequence identity with the amino acid sequence shown in SEQ ID NO:78, wherein SEQ ID NO: 78 is as defined in the complete specification.